Therapeutics for treatment of COVID-19 symptoms
AssigneeThe Texas A&M University System
InventorsRichard H. Gomer, Darrell Pilling, Tejas Karhadkar
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating compounds. The methods can involve administering CALD-treating compounds to a patient suffering from CALD or cytokine storm.
Claims37
A method of treating COVID-19-associated lung damage (CALD), the method comprising administering to a patient with COVID-19 an effective amount of a pharmaceutical formulation comprising compound II
A method of treating CALD, the method comprising administering to a patient having an oxygen level of less than 90% as measured by pulse oximetry and a pulmonary compliance of greater than 50 ml/cm H2O an effective amount of a pharmaceutical formulation comprising compound II.
A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-1β greater than 3.2 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-6 greater than 7 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-12p70 greater than 40 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-23 greater than 15 pg/ml an effective amount of a pharmaceutical formulation comprising compound II.
A method of treatment of cytokine storm, the method comprising administering to a patient having a serum level of interleukin-27 greater than 1 ng/ml an effective amount of a pharmaceutical formulation comprising compound II.
A method of treatment of cytokine storm, the method comprising administering to a patient having a D-dimer level of greater than 1 μg/ml an effective amount of a pharmaceutical formulation comprising compound II.
Dependencies are inferred from the claim text.